Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor +/- Imatinib in GIST
NCT04138381Phase 2Unknown
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Aug 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Spanish Group for Research on Sarcoma. Primary endpoints: Maximum Tolerated Dose at 32 months and Clinical Benefit Rate at 24 months. Status: unknown.
02
Drugs
selinexor
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04138381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138381.